🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Come meet #CBPartners at #ISPOR during one of our workshops or Sunday for our symposium! We will be in Montréal from Sunday to Wednesday!

#CBPartners will be leading the #ISPOR Sunday night symposium translating trial evidence to P&R outcomes - join us in 518abc (5th Floor)

Welcome to #ISPORMontreal! Visit #CBPartners during/after our symposium on evidence translation into P&R decisions tonight at 1830 in 518abc

Last day at #ASCO14 - let us know if you want to meet up to recap learnings from the meeting!

Message us for #CBPartners' thought piece on the US pricing environment: while #SOVALDI raises some issues, it is hardly a tipping point.

CBPartners' latest thought piece on US #pricing trends for specialty / #oncology therapeutics is now available - message for your free copy!

Attending #ISPORBeijing next week? #CBPartners will be attending with VP Emerging Markets and consultants from local offices - let's meet!

Still at #ISPORBeijing? Swing by Hall 5A for a rigorous discussion w/ #CBPartners around how #HTA affects innovation - starting now!

Something big is coming from #CBPartners! Stay tuned for the announcement in the coming days. #pharmapricing #iphone

#CBPartners is a proud sponsor of this past weekend's National MS Society National MS Society bike race! Go Team!

#CBPartners has officially launched its app, complete w/ over 80 countries' IRP rules - download your free copy now!…bit.ly/CBPartnersApp

Download the fastest growing #pharma app on iTunes - CBPartners' #IRP app covers over 80 countries, w/ live updates.…bit.ly/CBPartnersApp

Find out what hundreds in #pharma already have - download the free #IRP app covering >80 countries and live updates bit.ly/CBPartnersApp…

In time for #ISPOR, CBPartners latest thought piece on 'Alternative Access Pathways' to be launched this weekend! Message for a free copy!

CBPartners' Russia expert, David Yampolsky shares some of the latest on the market's Seven Nosologies / VZN programm…lnkd.in/ekxpfpD

Nice write-up on #raredisease P&MA from CBPartners round-table w/ Sandeep Duttagupta & Monica Martin de Bustamante bit.ly/1QMCksg

CBPartners is launching its latest thought piece on Oncology Portfolio Design this week - please message to receive…lnkd.in/ecw6vqm

Is the concept of 'International HTA Referencing' (IHR) taking hold in GRC?  As its economy continues to struggle wi…lnkd.in/g2qh5HQ

The PD-1 / PD-L1 race has been a wild one - it's time to catch up on who is leading, and whether new entrants have r…lnkd.in/e8XfzcQ

$GSK's recent success with STRIMVELIS™ via NICE's HST pathway should surprise no one.  Yes, the evidence presented a…lnkd.in/e9xkwXG